📇 Rhumatologue · MAGNY EN VEXIN · (95) · Salarié

M HASSAN KHOUBAIZ

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
26 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
82.6 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 MAGNY EN VEXIN (95)SalariéRPPS 10001547735

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

HOPITAL NOVO SITE MAGNY EN VEXIN
38 R CARNOT, 95420 MAGNY EN VEXIN
☎ 0134794444Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression

Diabetes, obesity & metabolism · 2026

📚 1 citations

Lire l'abstract Crossref ↓

ABSTRACT Background Obesity is a complex chronic disease requiring effective long‐term management. We performed a systematic review and meta‐analysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity. Methods We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss. Efficacy outcomes were percentage change in body weight, absolute change in body weight, fasting plasma glucose, HbA1c, and BMI. Lipid parameters included total cholesterol, LDL‐C, HDL‐C, VLDL‐C, and triglycerides. A random‐effects model was used to estimate mean differences (MD) or risk ratios (RR) with 95% CIs. Results Three RCTs ( n = 3545) were included. Cagrisema produced significantly greater percentage [MD −7.47% (95% CI: −10.58, −4.36); p < 0.001] and absolute [MD −7.60 kg (95% CI: −10.33, −4.86); p < 0.001] weight loss than semaglutide. Cagrilintide monotherapy weight loss was comparable to semaglutide. Lipids parameters were mostly similar between groups, though LDL‐C was modestly higher with combination therapy versus semaglutide [MD 0.29 mmol/L (95% CI: 0.02, 0.55); p = 0.03]. Overall and serious adverse events were comparable between cagrisema and semaglutide, but combination therapy increased administration‐site conditions [RR 3.27 (95% CI: 1.27, 8.46)] and nausea [RR 1.64 (95% CI: 1.01, 2.66)]. Cagrilintide monotherapy had a higher risk of serious adverse events [RR 1.83 (95% CI: 1.03, 3.24)] compared to semaglutide. Conclusion Cagrisema is more effective than semaglutide in reducing weight and increasing glycemic control. Cagrisema is safe and has a comparable side effect profile to currently accepted treatments. This regimen has enormous potential in dual‐agonist therapy for obese patients.

Prophylactic clipping after colorectal endoscopic submucosal dissection in randomized controlled trials: a systematic review and meta-analysis

Endoscopy · 2026

📚 1 citations🩺 Clinique

Lire l'abstract Crossref ↓

Abstract Endoscopic submucosal dissection (ESD) is a minimally invasive and effective treatment for large nonpedunculated colorectal polyps; however, it carries a relevant risk of adverse events (AEs), such as delayed bleeding, as well as postprocedural perforation (PPP) and postelectrocoagulation syndrome (PECS). Systematic defect closure may reduce these risks, but its preventive efficacy remains uncertain. We conducted a meta-analysis of randomized controlled trials (RCTs) to assess the efficacy of prophylactic clipping after colorectal ESD. Following PRISMA guidelines, we searched MEDLINE, Embase, and SCOPUS through to June 2025 for RCTs comparing prophylactic clipping vs. no clipping after colorectal ESD in adults. The primary outcome was clinically significant delayed bleeding; secondary outcomes included PPP and PECS, as well as subanalysis by location and size. Random-effects models were used to compute risk ratios (RRs) and 95%CIs. Four RCTs from Asia including 684 patients were analyzed (336 with clipping, 348 controls). Prophylactic clipping significantly reduced clinically significant delayed bleeding risk (0.3% vs. 3.4%; RR 0.26, 95%CI 0.08–0.88). No significant differences were found for PPP (0.4% vs. 1.0%; RR 0.74; 95%CI 0.23–2.35) or PECS (12.2% vs. 11.8%; RR 1.06; 95%CI 0.74–1.52). Subgroup analyses by lesion size (>30 mm vs. <30 mm) and location (proximal vs. distal colon) were not significant. A 74% decrease in the risk of clinically significant delayed bleeding is achieved by prophylactic clipping after colorectal ESD, supporting its adoption in routine practice.

Cookies & analyse de trafic

M HASSAN KHOUBAIZ

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (26) — classées par pathologie

Revue générale10

Revue / méta-analyse7

Transversal5

Pédiatrie4

Épidémiologie & registres2

Essai clinique2

IA en rhumatologie2

Vraie vie / RWE2

Case report / série1

Économie santé1

Pharmacovigilance1

Qualité de vie / PROMs1

Santé mentale / fatigue1

Partager cette fiche